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Anemia is a common complication of chronic kidney disease
(CKD), but the outcomes associated with lower hemoglobin
(Hgb) levels in patients with CKD not yet on dialysis are not
well characterized. Analyses exploring outcomes associated
with a single baseline Hgb value also do not account for the
longitudinal variation of this measure. After collecting all Hgb
measurements (N¼ 17 194, median (range): 12 (1–168)) over
a median follow-up period of 2.1 years in a historical
prospective cohort of 853 male US veterans with CKD Stages
3–5 not yet on dialysis, we examined the association of
time-averaged Hgb levels with predialysis all-cause mortality,
end-stage renal disease (ESRD), and a composite end point of
both. Kaplan–Meier survival analysis and Cox models
adjusted for age, race, body mass index, smoking status,
blood pressure, diabetes mellitus, cardiovascular disease,
categories of estimated glomerular filtration rate, serum
concentrations of albumin and cholesterol, and proteinuria
were examined. Lower time-averaged Hgb was associated
with significantly higher hazard of the composite end point
(hazard ratio (95% confidence interval) in the adjusted model
for time-averaged Hgb of o110, 111–120 and 121–130,
compared to 4130 g/l: 2.57 (1.85–3.58), 1.97 (1.45–2.66), 1.19
(0.86–1.63), Ptrendo0.001). Lower time-averaged Hgb was
associated with both significantly higher pre-dialysis
mortality and higher risk of ESRD, when analyzed separately.
Anemia (especially time-averaged Hgb o120 g/l) is
associated with both higher mortality and increased risk of
ESRD in male patients with CKD not yet on dialysis.
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Anemia is commonly present in patients with chronic kidney
disease (CKD).1 The consequences of lower hemoglobin
(Hgb) levels in patients with CKD Stage 5 on dialysis are well
studied, and include increased morbidity and mortality.2–5
Fewer data exist on the effects of anemia in patients with
CKD Stages 3–5 not yet on dialysis. Additionally, descriptive
studies exploring the association of a single baseline Hgb
value with various outcomes cannot account for the long-
itudinal variation of Hgb levels. We describe the association
of anemia with major clinical outcomes (pre-dialysis all-
cause mortality and end-stage renal disease (ESRD)) in a
cohort of 853 male US veterans with CKD Stages 3–5 not yet
on dialysis. We collected Hgb measurements longitudinally
and examined time-averaged Hgb values to capture the
temporal variation in Hgb levels.
RESULTS
Baseline characteristics divided by categories of time-
averaged Hgb are presented in Table 1. Patients with higher
time-averaged Hgb were more likely to be white and non-
diabetic, and had higher estimated glomerular filtration rate
(GFR), albumin and cholesterol levels, and lower 24 h urine
protein level (Table 1). The baseline characteristics of the 36
patients lost to follow-up were not significantly different
from the overall patient groups’ (data not shown). The
median duration of follow-up was 2.1 years and total time at
risk was 2414 patient-years. Four hundred forty patients
reached the composite end point (event rate (95% confidence
interval (CI)): 182.2 (166.0–200.1)/1000 patient-years), with
245 patients dying and 195 patients starting dialysis. Table 2
shows the distribution of events by categories of time-
averaged Hgb. Patients with lower time-averaged Hgb
experienced a higher number of both the primary and the
secondary events (Table 2). Figure 1 shows the hazard ratios
(95% CI) for the composite end point, by categories of time-
averaged Hgb, in a Cox model, both unadjusted and after
adjustment for age, race, diabetes mellitus (DM), athero-
sclerotic cardiovascular disease (ASCVD), body mass index
(BMI), smoking status, mean arterial pressure (MAP),
estimated GFR, serum albumin, blood cholesterol, and 24-h
urine protein level. In both models, lower time-averaged Hgb
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was associated with higher hazard ratio for the composite
outcome, with a significant linear trend noted (Figure 1). In a
Cox model including time-averaged Hgb as a continuous
variable, a 10 g/l higher time-averaged Hgb was associated
with a hazard ratio (95% CI) of 0.79 (0.73–0.85) for the
composite outcome (Po0.001).
Figures 2 and 3 show the hazard ratios (95% CI) for pre-
dialysis all-cause mortality (Figure 2) and ESRD (Figure 3),
by categories of time-averaged Hgb, both unadjusted and
after adjustment for age, race, DM, ASCVD, BMI, smoking
status, MAP, estimated GFR, serum albumin, blood choles-
terol, and 24-h urine protein. In both cases, lower time-
averaged Hgb was associated with higher hazard ratios for the
studied outcomes, with a significant linear trend (Figures 2
and 3). Patients with time-averaged Hgb of o110 g/l had the
highest hazard ratio (95% CI) for all-cause mortality (2.06
(1.35–3.13)) and for ESRD (2.96 (1.70–5.14)), but even
patients with time-averaged Hgb 111–120 g/l had significantly
higher hazard ratios for both mortality (1.80 (1.23–2.63)) and
Table 1 | Baseline characteristics of individuals stratified by categories of time-averaged hemoglobin levela
o110 (N=174) 111–120 (N=216) 121–130 (N=201) 4130 (N=262) P
Age (years) 68.6710.6 68.9710.3 68.3710.5 67.0710.8 0.1
Race (% black) 55 (31.6) 61 (28.2) 46 (22.9) 47 (17.9) 0.005
DM 102 (58.6) 128 (59.3) 108 (53.7) 112 (42.7) 0.001
Hypertension 161 (92.5) 205 (94.9) 193 (96.0) 246 (93.9) 0.5
ASCVD 113 (64.9) 133 (61.6) 123 (61.2) 152 (58.0) 0.5
Smoking 48 (30.8) 46 (23.6) 55 (28.3) 66 (26.5) 0.4
BMI (kg/m2) 28.776.6 28.075.5 29.075.2 29.175.5 0.2
MAP (mmHg) 102.1718.6 102.1715.9 99.9717.7 101.1717.2 0.5
GFR (ml/min/1.73m2) 27.3712.5 31.3711.4 33.9710.2 37.079.8 o0.0001
Albumin (g/l) 3476 3575 3675 3874 o0.0001
Cholesterol (mmol/l)b 4.52 (4.33–4.72) 4.90 (4.73–5.08) 4.83 (4.65–5.02) 4.96 (4.81–5.12) 0.004
Proteinuria (g/24 h)b 1.4 (1.2–1.8) 1.1 (0.8–1.4) 0.7 (0.5–0.9) 0.4 (0.3–0.5) o0.0001
ASCVD=atherosclerotic cardiovascular disease; BMI=body mass index; DM=diabetes mellitus; GFR=glomerular filtration rate; MAP=mean arterial pressure.
Comparisons are made by ANOVA, Fisher’s exact test or w2 test.
aData presented as means7s.d., number (% of total).
bGeometric means (95% CI).
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Figure 1 | Graphic representation of the hazard ratio (95% CI) of
the composite outcome of pre-dialysis all-cause mortality and
ESRD associated with different levels of time-averaged Hgb,
unadjusted and after adjustment for age, race, DM, ASCVD, BMI,
smoking status, MAP, estimated GFR, serum albumin, blood
cholesterol, and 24-h urine protein. The group with time-averaged
Hgb 4130 g/l served as reference.
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Figure 2 | Graphic representation of the hazard ratio (95% CI) of
pre-dialysis all-cause mortality associated with different levels of
time-averaged Hgb, unadjusted and after adjustment for age,
race, DM, ASCVD, BMI, smoking status, MAP, estimated GFR,
serum albumin, blood cholesterol, and 24-h urine protein. The
group with time-averaged Hgb 4130 g/l served as reference.
Table 2 | Distribution of events, by categories of time-
averaged hemoglobin levela
Composite
(N=440)
Death before dialysis
(N=245)
Dialysis
(N=195)
o110 g/l (N=174) 138 (79.3%) 68 (39.0%) 70 (40.2%)
111–120 g/l
(N=216)
139 (64.3%) 74 (34.2%) 65 (30.0%)
121–130 g/l
(N=201)
86 (42.8%) 50 (24.9%) 36 (17.9%)
4130 g/l (N=262) 77 (29.4%) 53 (20.2%) 24 (9.2%)
aData presented as number (% of total).
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Figure 3 | Graphic representation of the hazard ratio (95% CI) of
ESRD associated with different levels of time-averaged Hgb,
unadjusted and after adjustment for age, race, DM, ASCVD, BMI,
smoking status, MAP, estimated GFR, serum albumin, blood
cholesterol, and 24-h urine protein. The group with time-averaged
Hgb 4130 g/l served as reference.
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ESRD (1.81 (1.07–3.05)) compared to the group with
time-averaged Hgb 4130 g/l. There was no significant
difference in outcomes between the time-averaged Hgb
121–130 and 4130 g/l groups (Figures 2 and 3). In Cox
models including time-averaged Hgb as a continuous
variable, a 10 g/l higher time-averaged Hgb was associated
with a hazard ratio (95% CI) of 0.86 (0.78–0.95) for all-cause
mortality (P¼ 0.001) and 0.74 (0.65–0.84) for ESRD
(Po0.001). Older age, prevalent ASCVD, lower MAP, lower
albumin, lower cholesterol, lower proteinuria, and lower GFR
were also associated with significantly higher risk of all-cause
mortality and younger age, prevalent DM, higher proteinuria
and lower GFR were also associated with significantly higher
risk of ESRD in the Cox models.
The associations between time-averaged Hgb and the
studied outcomes remained significant in all the examined
subgroups (Figure 4). Inclusion of interaction terms in the
statistical model also revealed no significant interaction with
any of the studied covariates. The associations between time-
averaged Hgb and the studied outcomes were similar when
analyses were performed including non-imputed data only
and also after inclusion of the eight female patients (results
not shown).
DISCUSSION
We examined the association of anemia with clinical
outcomes (pre-dialysis all-cause mortality and ESRD) in a
cohort of male US veterans with moderate and severe CKD.
As blood Hgb concentration varies longitudinally in patients
with CKD as a result of changing kidney function,1 treatment
measures6,7 and various states of illness, using a single
baseline measure does not provide an accurate assessment of
the individual patients’ exposure to the effects of anemia over
time. To account for this, we used the time-averaged Hgb in
each individual patient, a value that makes it possible to
assess the longitudinal burden of anemia by averaging all the
individual measurements and accounting for the duration of
any individual measurement value. We found that time-
averaged Hgb values below 120 g/l were associated with
significantly higher hazard ratios for both pre-dialysis all-
cause mortality and ESRD, with a significant linear trend
toward higher hazard ratios with lower time-averaged Hgb
levels. This association was consistent in all studied
subgroups, suggesting that low Hgb is an independent risk
factor for the above outcomes, rather than a surrogate marker
of another concomitant condition.
Anemia is a frequent complication of CKD,1 and the
prevalence of anemia increases as kidney function declines.1
Studies in dialysis patients have shown an increased mortality
with lower Hgb levels,2–4 but relatively little is known about
this in patients who have CKD but are not yet on dialysis. In
a middle-aged community-based population, anemia was
associated with higher incidence of coronary events8 and
stroke9 in patients with elevated serum creatinine levels.
Anemia and CKD were also shown to be risk factors for death
in hospitalized patients with congestive heart failure10 and
acute myocardial infarction.11 Treatment of anemia prior to
initiation of dialysis confers a survival advantage after the
start of dialysis,12,13 it ameliorates left ventricular hypertro-
phy and it improves quality of life and various health
measures.14–17 Anemia was also associated with higher all-
cause and cardiovascular mortality in a sample of patients
with CKD pooled from various prospective studies.18 The
patients in this study, however, had less advanced CKD
(mean estimated GFR 51 ml/min/1.73m2), and the study used
a single baseline Hgb to define anemia.18 Our study is to our
knowledge the first to examine pre-dialysis mortality in an
unselected patient group with moderate and advanced CKD,
and also account for the longitudinal variation of Hgb levels,
whereas addressing the confounding effects of multiple other
potential risk factors.
Anemia could increase mortality by its effect on the
development of left ventricular hypertrophy, which is a risk
factor for mortality in patients on dialysis.19 Lower Hgb is
associated with left ventricular hypertrophy and treatment of
anemia was shown to result in regression of left ventricular
hypertrophy.14,15
An association of anemia with progression of CKD has
been proposed in the past, as treatment of anemia
ameliorated the loss of kidney function and progression to
ESRD.17,20,21 Our findings are in agreement with these
results, as we found that lower time-averaged Hgb values
were associated with higher hazard ratios for ESRD, even
after adjustment for several confounders. The mechanisms
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Figure 4 | Adjusted hazard of the composite end point of pre-
dialysis all-cause mortality and ESRD associated with a 10 g/l
higher time-averaged Hgb level, by subgroups. Models are
adjusted for age, race, DM, ASCVD, BMI, smoking status, MAP,
estimated GFR, serum albumin, blood cholesterol, and 24-h urine
protein. CI, confidence interval; DM, diabetes mellitus; ASCVD,
atherosclerotic cardiovascular disease; BMI, body mass index;
GFR, glomerular filtration rate.
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involved in the association of anemia with progression of
CKD may involve hypoxia-induced tubulointerstitial fibrosis,
and treatment with recombinant human erythropoietin may
have additional benefits beyond decreasing tissue hypoxia,
such as antiapoptotic and antioxidant effects.22
Several shortcomings of our study need to be stressed. Our
cohort was derived from a single medical center, and we
examined an exclusively male group of patients; hence, our
findings may not apply to females or patients from other
geographic locations. We did not have cause of death
available for our analyses, hence we could not test the
hypothesis that anemia could increase mortality by impacting
on cardiovascular disease-related factors such as left ventri-
cular hypertrophy. Given the retrospective nature of our
study, associations, but no cause–effect relationships can be
established from it. While we tried to account for several
potential confounding risk factors, the presence of residual
confounding cannot be excluded. Even so, the uniformity of
the detected associations across a wide array of subgroups,
and the lack of any significant interactions make it more
likely that anemia is an independent risk factor for the
studied outcomes. Another shortcoming of our study is that
we did not account for the effects of therapeutic interven-
tions with recombinant human erythropoietin or angio-
tensin-converting enzyme inhibitors/angiotensin II receptor
blockers. The major effect of recombinant human erythro-
poietin treatment is an increase in Hgb levels,6 and by
collecting longitudinal Hgb values, we would have captured
such a benefit. Additionally though, there could be other
benefits of treatment with EPO that go beyond increasing
Hgb levels.22 Although the effects of such benefits would have
been missed in our study, this is only a theoretical concern, as
the mentioned benefits have not yet been proven in human
studies. Therapy with angiotensin-converting enzyme in-
hibitors/angiotensin II receptor blockers could have impacted
the examined associations in different ways: first, angio-
tensin-converting enzyme inhibitor/angiotensin II receptor
blockers has been shown to favorably impact the progression
of CKD,23–25 and second, angiotensin-converting enzyme
inhibitor/angiotensin II receptor blockers have been shown
to lower Hgb concentrations in polycythemic patients;26–28
hence, a negative effect of such therapies on time-averaged
Hgb levels in our study cannot be ruled out. Additionally, we
could not assess the impact of changing therapeutic practices
on outcomes, given the shift in general usage patterns for
both recombinant human erythropoietin and angiotensin-
converting enzyme inhibitor/angiotensin II receptor blockers
during the studied time period. Finally, the use of a single
time-averaged value of Hgb did not allow for capturing
dynamic changes in Hgb levels (such as the direction of
change over time) and their effects on outcomes, even though
it made possible to account for overall temporal variations.
CONCLUSION
We have found that anemia is independently associated with
higher risk of pre-dialysis mortality and ESRD in male
patients with CKD Stages 3–5 not yet on dialysis. Patients
with time-averaged Hgb values o120 g/l had significantly
higher relative risks of these outcomes, and the benefit of a
time-averaged Hgb 4120 g/l appeared to have no upper
limit. Our findings could serve as basis for randomized
controlled studies in order to establish an ideal therapeutic
goal for the treatment of anemia in pre-dialysis CKD.
MATERIALS AND METHODS
Study population
We examined patients referred for evaluation to a single Nephrology
clinic at Salem Veterans Affairs Medical Center between January 1,
1990 and December 31, 2004. After patients with a kidney
transplant, patients on dialysis and patients referred for problems
other than CKD were excluded, 960 patients with CKD not yet on
dialysis were identified. GFR was estimated using the abbreviated
equation developed for the Modification of Diet in Renal Disease
Study,29 and patients were classified according to the Kidney/
Dialysis Outcome Quality Initiative Clinical Practice Guidelines for
CKD: Evaluation, Classification and Stratification.30 Ninety nine
patients with CKD Stages 1 and 2 were excluded. As there were only
eight female patients left in the remaining cohort, they were also
excluded from further analyses, leaving the final number of patients
available for analysis at 853.
Data collection
We collected baseline data from medical records (paper and
electronic) at the time of the initial encounter in the Nephrology
clinic, including demographic and anthropometric information,
comorbidities, blood pressure measurements, and laboratory
measures. BMI was calculated as the weight in kilogram divided
by the square of the height in meters. DM was defined as the
presence of an abnormal fasting glucose level or antidiabetic therapy.
Hypertension was defined as the presence of an abnormal blood
pressure measurement (defined as a systolic blood pressure
4140 mmHg or a diastolic blood pressure 490 mmHg) or
antihypertensive therapy. ASCVD was defined as a previous history
of cardiovascular, cerebrovascular or peripheral vascular disease,
based on chart review. Additionally, we collected all Hgb measure-
ments longitudinally from the time of the initial encounter until the
end of follow-up (total of 17 194 measurements, median (range): 12
(1–168)), and calculated time-averaged values for each patient
individually, using the following formula:
Time  averaged Hgb
¼ 1
2ðtn  t0Þ
Xn
i¼1
ðHgbi þ Hgbi1Þðti  ti1Þ;
where Hgb values Hgb0, Hgb1, y, Hgbn were measured at time
points t0, t1, y, tn.
Outcomes
We followed patients until death or loss of follow-up, or until June
16, 2005. We considered a patient lost to follow-up if no contact
with the medical center was documented for more than 6 months.
Thirty-six patients (4.2%) were lost to follow-up. Our outcome
measures of interest were mortality and ESRD. We recorded deaths
from the VA centralized patient record system, which uses a
combination of sources including national databases from the
Veterans Health Administration, direct notifications from family
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members and obituaries to ascertain the death of an enrolled
veteran. No data was available on cause of death; hence, the studied
outcome measure was all-cause mortality. ESRD was defined as the
initiation of dialysis (hemodialysis or peritoneal dialysis), and was
ascertained from local medical records.
Statistical analysis
After descriptive statistics, variables with skewed distribution were
transformed to their natural logarithm. We imputed missing data
points for 24-h urine protein (3.9% missing), blood cholesterol
(1.2% missing) and serum albumin (1.0% missing) using linear
regression with all other patient characteristics serving as indepen-
dent variables. Given the large number of missing data points for
BMI (24.3% missing), we categorized this variable by using quartiles
and adding a ‘missing’ category as a fifth group. Similarly, we
analyzed smoking status (6.8% missing) as a categorical variable
with three categories (non-smoker, active smoker and ‘missing
smoking status’). Analyses were repeated with the inclusion of the
female participants and using non-imputed data only.
Survival modeling. The starting time for survival analysis was
the date of the initial encounter and the main outcome measure was
the composite of pre-dialysis all-cause mortality and ESRD.
Secondary outcome measures were mortality and ESRD analyzed
separately. We censored patients lost to follow-up at the date of the
last documented contact with the medical center. Event rates were
calculated using the person-years approach. We analyzed the
unadjusted association of categorized time-averaged Hgb with all-
cause mortality using Kaplan–Meier plots and the log-rank test. To
examine the effect of potentially confounding variables, we adjusted
in a multivariable Cox model for patient age, race, DM, ASCVD,
BMI, smoking status, MAP, estimated GFR, serum albumin, blood
cholesterol, and 24-h urine protein levels. We performed subgroup
analyses in groups divided by age, race, DM, ASCVD, smoking
status and levels of MAP, BMI, estimated GFR, albumin, cholesterol
and proteinuria, and we explored potential interactions by inclusion
of interaction terms. We tested the proportionality assumption
using plots and interaction terms with time. We considered P-values
of less than 0.05 significant. Statistical analyses were performed
using STATA statistical software Version 8 (STATA Corporation,
College Station, TX, USA).
The study protocol was approved by the Research and
Development Committee and the Human Studies Sub-Committee
at the Salem Veterans Affairs Medical Center.
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